Progress in Hepatocellular Carcinoma Treatment

K. Okita (Herausgeber)

Buch | Softcover

107 Seiten

2012 | Softcover reprint of the original 1st ed. 2000
Springer Verlag, Japan
978-4-431-67983-7 (ISBN)

Artikel merken

According to a recent report from the Japanese Ministry of Health and Welfare, the mortality rate for hepatocellular carcinoma (HCC) is more than 30 per 100000 pop ulation. In addition,epidemiologists predictan increase in this figure by the year 2015, because of the rather high incidence of chronic liver diseases caused by HCY. The same situation has been observed in other Asian countries. It seems that HCC is likely to be an endemic disease, because of the higher preva lence of chronic hepatitis and liver cirrhosis caused by HBV, HCV, and/or aflatoxins in Asian and African countries. We also note that an interesting paper appeared in a recent issue of the New England Journal of Medicine describing the increase in younger HCC patients in the United States as compared with past decades. At present, silent hepatitis C infection is now smoldering in 4 million mostly unsuspecting Americans. Those carriers will be candidates for chronic liver disease, which is a pre disposing factor for the development of HCC. In Europe there are an estimated 5 million carriers. Accordingly, it is important to do all we can to reduce the prevalence of HCC not only in African and Asian countries, but also in the United States and Europe. With this perspective,last year the Japanese Society for Hepatology, in cooperation with the Ministry of Health and Welfare, initiated a national campaign to fight HCC.

The Efficacy of the Ultrasonographic Screening Test for Early Detection of Hepatocellular Carcinoma and Risk Factors of HCC in Korea.- Percutaneous Ethanol Injection Therapy, Percutaneous Infarction Therapy, and Percutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma.- Percutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma.- Percutaneous Ablation of Hepatocellular Carcinoma.- Treatment with Subsegmental Transcatheter Arterial Embolization for Hepatocellular Carcinoma: Prognosis, Recurrence, and Effect on Liver Function.- Clinical Significance of Liposome-Encapsulated OK-432 Injection with Simultaneous Interventional Radiological Treatment of Hepatocellular Carcinoma Based on Experimental Analysis of Liver-Associated Lymphocytes.- Phase II Trial of Hepatic Arterial Infusion Chemotherapy Using Cisplatin and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.- Surgical Treatment of Hepatocellular Carcinoma.- Transjugular Intrahepatic Portosystemic Shunt for Patients with Hepatocellular Carcinoma.- Prevention of Hepatocarcinogenesis by Fibrosuppression.- Cancer Vaccination by B7-1-Transfected Hepatocellular Carcinoma Cells.- Clonal Deletion, A Novel Strategy of Cancer Control that Falls Between Cancer Chemoprevention and Cancer Chemotherapy: A Clinical Experience in Liver Cancer.

Zusatzinfo	XI, 107 p.
Verlagsort	Tokyo
Sprache	englisch
Maße	155 x 235 mm
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Gastroenterologie
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Hepatologie
ISBN-10	4-431-67983-9 / 4431679839
ISBN-13	978-4-431-67983-7 / 9784431679837
Zustand	Neuware